Skip to content
akaturk Academic measurement
Sign in Register

OpenAlex topic

Bladder and Urothelial Cancer Treatments

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 2,906 works 117 author topics

Works

2,906 works

  1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer 2024
    OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. METHODS: We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and…

  2. The International Society of Urological Pathology ISUP Grading System for Renal Cell Carcinoma and Other Prognostic Parameters 2013
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morp…

  3. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  4. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  5. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial 2021
    OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  6. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 2020
    OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment…

  7. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma 2023
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. METHODS: In this phase 3, multinational, open-label trial, we randomly assigned patients with previously untreated unresectable or metastatic ur…

  8. Adjuvant Chemotherapy for Invasive Bladder Cancer A 2013 Updated Systematic Review and Meta Analysis of Randomized Trials 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    No abstract yet.

  9. The Urinary Tract Microbiome in Health and Disease 2016
    OpenAlex top 10% OpenAlex 98.1%

    No abstract yet.

  10. Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective Randomised Clinical Trial 2010
    OpenAlex top 1% OpenAlex 99.4%

    No abstract yet.

  11. An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.7%

    Extracellular vesicles (EVs), including exosomes and microvesicles, are present in a variety of bodily fluids, and the concentration of these sub-cellular vesicles and their associated biomarkers (proteins, nucleic acids, and lipids) can be used to aid clinical diagnosis. Although ultracentrifugation is commonly used…

  12. The Effect of Repeat Transurethral Resection on Recurrence and Progression Rates in Patients With T1 Tumors of the Bladder Who Received Intravesical Mitomycin: A Prospective, Randomized Clinical Trial 2006
    OpenAlex top 10% OpenAlex 98.5%

    PURPOSE: We compared the outcomes of repeat transurethral resection plus intravesical mitomycin C with initial transurethral resection of bladder plus intravesical MMC in patients with newly diagnosed pT1 transitional cell carcinoma of the bladder in terms of recurrence, progression and overall survival. MATERIALS AND…

Academicians

117 academicians